ATE207365T1 - Polyribosylribitol-phosphat enthaltende haemophilus-influenzae-typ-b-impfstoffzubereitu g und verfahren zu deren herstellung - Google Patents

Polyribosylribitol-phosphat enthaltende haemophilus-influenzae-typ-b-impfstoffzubereitu g und verfahren zu deren herstellung

Info

Publication number
ATE207365T1
ATE207365T1 AT96917554T AT96917554T ATE207365T1 AT E207365 T1 ATE207365 T1 AT E207365T1 AT 96917554 T AT96917554 T AT 96917554T AT 96917554 T AT96917554 T AT 96917554T AT E207365 T1 ATE207365 T1 AT E207365T1
Authority
AT
Austria
Prior art keywords
haemophilus influenzae
production
influenzae type
preparation containing
vaccine preparation
Prior art date
Application number
AT96917554T
Other languages
English (en)
Inventor
Francois Arminjon
Jean-Rene Cartier
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9479510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE207365(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Application granted granted Critical
Publication of ATE207365T1 publication Critical patent/ATE207365T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT96917554T 1995-05-24 1996-05-24 Polyribosylribitol-phosphat enthaltende haemophilus-influenzae-typ-b-impfstoffzubereitu g und verfahren zu deren herstellung ATE207365T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9506417A FR2734484B1 (fr) 1995-05-24 1995-05-24 Composition vaccinale liquide et procede de fabrication
PCT/FR1996/000791 WO1996037222A1 (fr) 1995-05-24 1996-05-24 Composition vaccinale comprenant du polyribosylribitol phosphate et son procede de fabrication

Publications (1)

Publication Number Publication Date
ATE207365T1 true ATE207365T1 (de) 2001-11-15

Family

ID=9479510

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96917554T ATE207365T1 (de) 1995-05-24 1996-05-24 Polyribosylribitol-phosphat enthaltende haemophilus-influenzae-typ-b-impfstoffzubereitu g und verfahren zu deren herstellung

Country Status (25)

Country Link
US (1) US6333036B1 (de)
EP (1) EP0828511B1 (de)
JP (1) JPH11505824A (de)
KR (1) KR100404312B1 (de)
CN (1) CN1152715C (de)
AT (1) ATE207365T1 (de)
BR (1) BR9608810C8 (de)
CA (1) CA2218764C (de)
CZ (1) CZ289810B6 (de)
DE (2) DE122011100030I1 (de)
DK (1) DK0828511T3 (de)
EA (1) EA000411B1 (de)
ES (1) ES2162067T3 (de)
FR (1) FR2734484B1 (de)
GR (1) GR3037011T3 (de)
HU (1) HU223941B1 (de)
LU (1) LU91924I2 (de)
NL (1) NL300231I2 (de)
NO (2) NO319579B1 (de)
NZ (1) NZ309829A (de)
PL (1) PL185846B1 (de)
PT (1) PT828511E (de)
SK (1) SK282500B6 (de)
TR (1) TR199701424T1 (de)
WO (1) WO1996037222A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020054884A1 (en) 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
US6974581B1 (en) * 1998-12-15 2005-12-13 Aventis Pasteur Limited Multi-component vaccine comprising at least two antigens from haemophilus influenzae to protect against disease
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
EP1674087A1 (de) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylaktische Verwendung von N-Methyl-D-Aspartat Rezeptor (NMDA) Antagonisten
FR2828406B1 (fr) 2001-08-08 2005-06-24 Aventis Pasteur Composition vaccinale bivalente havi
DK2353608T3 (da) 2002-10-11 2020-02-10 Novartis Vaccines And Diagnostics S R L Polypeptid-vacciner til bred beskyttelse mod hypervirulente meningokok-linjer
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
GB0313916D0 (en) * 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
SI1670506T1 (sl) 2003-10-02 2013-03-29 Novartis Ag Tekoča cepiva proti multiplim meningokoknim seroskupinam
EP1689721B1 (de) * 2003-11-26 2010-07-14 Pfizer Products Inc. Aminopyrazolderivate als gsk-3-inhibitoren
GB0405787D0 (en) * 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
SI1740217T1 (sl) 2004-04-30 2011-10-28 Novartis Ag Konjugirano meningokokno cepljenje
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
KR101540920B1 (ko) * 2007-07-26 2015-08-03 사노피 파스퇴르 리미티드 항원-애주번트 조성물 및 방법
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
PE20100365A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
PE20100366A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
US7814991B2 (en) * 2009-01-28 2010-10-19 Gas Technology Institute Process and apparatus for subterranean drilling
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
MA34084B1 (fr) * 2010-03-29 2013-03-05 Novartis Ag Composition comprenant le peptide amyloïde bêta 1-6 couplé à une particule de type virus et un adjuvant
CN103442730B (zh) 2011-01-05 2016-08-17 巴拉特生物技术国际有限公司 组合七价疫苗
EP2863943B1 (de) 2013-03-08 2016-07-13 Crucell Holland B.V. Nicht zellulärer pertussis-impfstoff
JP7526880B2 (ja) 2021-04-20 2024-08-01 Ｋｍバイオロジクス株式会社 ６種混合液状ワクチン組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1209036A (en) * 1982-08-20 1986-08-05 Joseph S.C. Kuo Combined haemophilus influenzae and diphtheria, pertussis, tetanus vaccine
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
EP0320942A3 (de) * 1987-12-18 1989-10-04 American Cyanamid Company Polysaccharide und makromolekulare Verbindungen davon
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
JP3626996B2 (ja) * 1992-05-23 2005-03-09 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム Ｂ型肝炎表面抗原および他の抗原からなる複合ワクチン

Also Published As

Publication number Publication date
CN1152715C (zh) 2004-06-09
FR2734484A1 (fr) 1996-11-29
MX9709011A (es) 1998-03-31
FR2734484B1 (fr) 1997-06-27
SK282500B6 (sk) 2002-10-08
CN1190898A (zh) 1998-08-19
NO975366L (no) 1997-11-21
CA2218764C (fr) 2011-01-11
BR9608810A (pt) 1999-08-31
HUP9901432A3 (en) 2000-03-28
CZ359797A3 (cs) 1999-06-16
LU91924I2 (fr) 2012-02-21
CZ289810B6 (cs) 2002-04-17
WO1996037222A1 (fr) 1996-11-28
ES2162067T3 (es) 2001-12-16
EA199700419A1 (ru) 1998-06-25
NO2011019I2 (no) 2015-05-18
PL323457A1 (en) 1998-03-30
TR199701424T1 (xx) 1998-03-21
EA000411B1 (ru) 1999-06-24
JPH11505824A (ja) 1999-05-25
PL185846B1 (pl) 2003-08-29
SK152997A3 (en) 1998-07-08
NL300231I1 (nl) 2006-07-03
DE69620271T2 (de) 2002-07-18
EP0828511A1 (de) 1998-03-18
NO2011019I1 (no) 2011-09-26
NO319579B1 (no) 2005-08-29
BR9608810C8 (pt) 2014-07-08
AU708777B2 (en) 1999-08-12
EP0828511B1 (de) 2001-10-24
GR3037011T3 (en) 2002-01-31
US6333036B1 (en) 2001-12-25
CA2218764A1 (fr) 1996-11-28
NO975366D0 (no) 1997-11-21
HUP9901432A2 (hu) 1999-08-30
AU6008696A (en) 1996-12-11
KR19990014919A (ko) 1999-02-25
DE122011100030I1 (de) 2011-12-08
DK0828511T3 (da) 2002-02-18
NL300231I2 (nl) 2006-09-01
HK1017251A1 (en) 1999-11-19
PT828511E (pt) 2002-02-28
DE69620271D1 (de) 2002-05-02
NZ309829A (en) 1999-06-29
HU223941B1 (hu) 2005-03-29
KR100404312B1 (ko) 2004-02-11

Similar Documents

Publication Publication Date Title
ATE207365T1 (de) Polyribosylribitol-phosphat enthaltende haemophilus-influenzae-typ-b-impfstoffzubereitu g und verfahren zu deren herstellung
BR9611533A (pt) Lipopoliamina composição e utilização e processo de preparação de uma lipopoliamina
HUP9900061A1 (hu) Alumínium-foszfátra adszorbeált konjugált poliszacharid antigént tartalmazó vakcinakompozíciók
PT99067A (pt) Processo para a producao de um conjugado de oligossacarido e de uma proteina veiculo
DE69104991D1 (de) Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.
ATE17082T1 (de) Verfahren zur herstellung von polysaccharidprotein-komplexenaus bakterienhuellen, die hergestellten produkte und dieselben enthaltende immunogenische zusammensetzungen.
ATE19734T1 (de) Heamophilus influenzae b polysaccharid exotoxoid konjugat-impfstoff.
MY109669A (en) N,o-sulphated heparosans, process for, preparing them and pharmaceutical compositions containing them
GB0313916D0 (en) Vaccine composition
SE9600716D0 (sv) Adhesion inhibitors, preparation comprising them and method for producing them
NZ223009A (en) Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens
ATE399022T1 (de) Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
DE59601683D1 (de) Sulfamat-derivate von 1,3,5(10)-estratrien-derivaten, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
BG98470A (bg) Метод за превръщане на липид-съдържащи бактериални капсуловани полизахариди в свободни от липид полизахариди
AU3313789A (en) Haemophilus influenza type B oxidized polysaccharide-outer membrane protein conjugate vaccine
ES8401722A1 (es) Procedimiento de obtencion de vacunas contra el patogeno h influenzae tipo b.
ATE7700T1 (de) 2-hydroxy-1,2,4-butantricarbonsaeure-oligoribosi - derivate, verfahren zu ihrer herstellung und ihre verwendung als prophylaktische mittel gegen zahnkaries.
KR930023369A (ko) 면역원성 포합체 및 그의 제조방법
ATE206619T1 (de) Komplex aus antigen und zellbestandteil, verfahren zur dessen herstellung und therapeutische verwendungen